Individuals with filaggrin-related eczema and asthma have increased long-term medication and hospital admission costs

Soares, P, Fidler, K, Felton, J, Tavendale, R, Hövels, A, Bremner, S A, Palmer, C N A and Mukhopadhyay, S (2018) Individuals with filaggrin-related eczema and asthma have increased long-term medication and hospital admission costs. British Journal Of Dermatology. ISSN 1365-2133 (Accepted)

[img] Microsoft Word - Accepted Version
Restricted to SRO admin only

Download (336kB)
[img] Microsoft Word (Supporting information) - Accepted Version
Restricted to SRO admin only

Download (23kB)

Abstract

Background: Eczema and asthma are chronic diseases with onset usually before the age of 5 years. More than 50% of individuals with eczema will develop asthma and/or other allergic diseases. Several loss-of-function mutations in the filaggrin gene have been identified in patients with eczema. However, the association of filaggrin in healthcare utilisation is unknown.
Objective: The aim of this study is to determine whether filaggrin mutations are associated with increased prescribing for eczema and asthma.
Methods: A secondary analysis of BREATHE, a cross-sectional study of gene-environment associations with asthma severity, was undertaken. BREATHE data was collected on 1100
participants with asthma, in Tayside and Fife, Scotland during the period 2003-2005. Through collaboration with the Health Informatics Centre in Dundee, BREATHE was linked to:
Accident & Emergency, community prescribing and Scottish Morbidity Records. The data linkage allowed longitudinal exploration of associations between genetic variation and
prescribing.
Results: An association was found between filaggrin mutations and increased prescribing for mild and moderate eczema, asthma reliever medicine and asthma exacerbations. A strong association was found between filaggrin mutations and prescribing of emollients (Incidence Rate Ratio (IRR): 2.19, 95% Confidence Interval (CI): 1.36-3.52), treatment for severe eczema (IRR: 2.18, 95% CI: 1.22-3.91) and a combination of long-acting β2-agonist and corticosteroids (IRR: 3.29, 95% CI: 1.68-6.43).Conclusions: The presence of filaggrin mutations in this cohort is associated with increased prescribing for eczema and asthma. Randomised controlled trials are required to determine if these individuals could benefit from management strategies to reduce morbidity and treatment costs.

Item Type: Article
Schools and Departments: Brighton and Sussex Medical School > Brighton and Sussex Medical School
Depositing User: Judy Keogh
Date Deposited: 05 Apr 2018 13:23
Last Modified: 21 May 2018 16:00
URI: http://sro.sussex.ac.uk/id/eprint/74828

View download statistics for this item

📧 Request an update